For the Inventor, By the Inventor

Enter assignee name

Bridgewater, NJ, United States of America

Reddy-Cheminor, Inc.

USPTO Granted Patents = 15

% Expired Patents = 6.7

Forward Citations = 237

Loading Chart...

Loading Chart...

17 inventors (with patents filed for the assignee):

Braj Bhushan Lohray (15 out of 37 patents)

Vidya Bhushan Lohray (15 out of 36 patents)

Rajagopalan Ramanujam (14 out of 37 patents)

4. Ranjan Chakrabarti (11 out of 35 patents)

5. Sekar Reddy Alla (6 out of 6 patents)

6. Rao Bheema Paraselli (5 out of 20 patents)

7. Shivaramayya Kalchar (4 out of 12 patents)

8. Ranga Madhavan Gurram (3 out of 16 patents)

9. Ashok Channaveerappa Bajji (3 out of 7 patents)

10. Reeba Kannimel Vikramadithyan (2 out of 4 patents)

11. Ashok Chennaveerappa Bajji (2 out of 2 patents)

12. Sarma Ks Pakala (1 out of 2 patents)

13. Prem Kumar Mamnoor (1 out of 2 patents)

14. Narayan Reddy Kommireddi (1 out of 1 patent)

15. Prasuna Guntupalli (1 out of 1 patent)

15 patents: Sort by Forward Citations

1. 7119198 - Tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them (2006-10-10),

2. 6159966 - Azolidinediones useful for the treatment of diabetes, dyslipidemia and (2000-12-12),

3. 6130214 - Benzothiazin and benzoxazin derivatives; their preparation and uses (2000-10-10),

4. 6114526 - Heterocyclic compounds, process for their preparation and pharmaceutical (2000-09-05),

5. 6054453 - Tricyclic compounds and their use in medicine process for their (2000-04-25),

6. 6051570 - Benzimidazole derivatives as antiulcer agents, process for their (2000-04-18),

7. 6030973 - Heterocyclic compounds having antidiabetic hypolipidemia and (2000-02-29),

8. 6011036 - Heterocyclic compounds having antidiabetic hypolipidemic (2000-01-04),

9. 6011031 - Azolidinediones useful for the treatment of diabetes, dyslipidemia and (2000-01-04),

10. 5985884 - Heterocyclic compounds, process for their preparation and pharmaceutical (1999-11-16),

11. 5919782 - Heterocyclic compounds having antidiabetic, hypolipidaemic, (1999-07-06),

12. 5889032 - Heterocyclic compounds having antidiabetic, hypolipidaemic, (1999-03-30),

13. 5889025 - Antidiabetic compounds having hypolipidaemic, antihypertensive (1999-03-30),

14. 5885997 - Heterocyclic compounds, process for their preparation and pharmaceutical (1999-03-23),

15. 5801173 - Heterocyclic compounds having antidiabetic, hypolipidaemic, (1998-09-01),

Company Overview

Reddy-Cheminor, Inc. is a prominent player in the pharmaceutical industry, specializing in the development and manufacturing of active pharmaceutical ingredients (APIs) and intermediates. The company focuses on providing high-quality solutions for various therapeutic areas, leveraging advanced technologies and research capabilities. Based in Bridgewater, NJ, Reddy-Cheminor serves a global market, emphasizing innovation and compliance with regulatory standards to meet the evolving needs of healthcare providers and patients.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

15 Patents

#18 in Bridgewater, NJ

#801 in New Jersey

#21,068 in US

#39,959 in the World

Bridgewater, NJ, United States of America

Reddy-Cheminor, Inc.

Forward Citations = 237

17 inventors:

Braj Bhushan Lohray (15 out of 37 patents)

Vidya Bhushan Lohray (15 out of 36 patents)

Rajagopalan Ramanujam (14 out of 37 patents)

4. Ranjan Chakrabarti (11 out of 35 patents)

5. Sekar Reddy Alla (6 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Reddy-Cheminor, Inc.. Retrieved from https://idiyas.com/company/reddy-cheminor

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…